​

Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MIRM Stock Forecast

Mirum Pharmaceuticals (MIRM) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $153.20, with a high of $200.00 and a low of $130.00. This represents a 84.36% increase from the last price of $83.10.

$50 $80 $110 $140 $170 $200 High: $200 Avg: $153.2 Low: $130 Last Closed Price: $83.1

MIRM Stock Rating

Mirum Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 1 Strong Buy (5.56%), 17 Buy (94.44%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 17 1 Strong Sell Sell Hold Buy Strong Buy

MIRM Price Target Upside V Benchmarks

TypeNameUpside
StockMirum Pharmaceuticals84.36%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts81345
Avg Price Target$159.75$150.00$132.64
Last Closing Price$83.10$83.10$83.10
Upside/Downside92.24%80.51%59.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26410---14
Sep, 26410---14
Aug, 2649---13
Jul, 26410---14
Jun, 2649---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2026Stifel Nicolaus$156.00$79.9695.10%87.73%
Oct 13, 2026Evercore ISI$146.00$83.5874.68%75.69%
Oct 12, 2026Morgan Stanley$152.00$86.0676.62%82.91%
Oct 12, 2026H.C. Wainwright$200.00$84.59136.43%140.67%
Oct 08, 2026RBC Capital$155.00$79.1995.73%86.52%
Sep 29, 2026Robert W. Baird$130.00$87.9647.79%56.44%
Sep 28, 2026Morgan Stanley$144.00$87.9663.71%73.29%
Sep 28, 2026H.C. Wainwright$195.00$87.00124.14%134.66%
Aug 27, 2026UBS$137.00$98.5139.07%64.86%
Aug 06, 2026Robert W. Baird$123.00$95.9128.25%48.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Evercore ISIOutperformOutperformhold
Oct 12, 2026Morgan StanleyOverweightOverweighthold
Oct 12, 2026Cowen & Co.BuyBuyhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Sep 29, 2026CitigroupBuyBuyhold
Sep 28, 2026CitigroupMarket OutperformMarket Outperformhold
Sep 28, 2026H.C. WainwrightBuyBuyhold
Aug 27, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 06, 2026H.C. WainwrightBuyBuyhold
Aug 06, 2026CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.77$-4.01$-4.00$-1.85$-0.47---
Avg Forecast$-4.48$-4.03$-3.37$-1.62$-0.62$0.62$2.92$4.97
High Forecast$-4.10$-3.79$-3.07$-0.43$0.83$4.99$6.98$5.97
Low Forecast$-5.21$-4.65$-3.62$-1.98$-1.28$-1.13$0.49$4.54
Surprise %-38.17%-0.50%18.69%14.20%-24.19%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.14M$77.06M$186.37M$336.89M$521.31M---
Avg Forecast$78.42M$76.00M$184.64M$333.95M$422.98M$521.39M$718.97M$919.96M
High Forecast$88.19M$84.88M$186.67M$336.76M$483.39M$521.39M$830.15M$1.06B
Low Forecast$73.23M$72.47M$179.31M$332.51M$396.78M$521.39M$670.45M$857.89M
Surprise %-75.60%1.40%0.94%0.88%23.25%---

Net Income Forecast

$-250M $-140M $-30M $80M $190M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.99M$-135.66M$-163.41M$-87.94M$-23.36M---
Avg Forecast$-183.22M$-164.93M$-136.73M$-49.23M$-36.95M$44.32M$162.92M$203.34M
High Forecast$-167.46M$-154.97M$-125.39M$-17.48M$33.78M$203.99M$285.38M$244.21M
Low Forecast$-212.90M$-189.98M$-148.08M$-80.98M$-52.35M$-46.16M$20.03M$185.50M
Surprise %-54.16%-17.74%19.51%78.64%-36.77%---

MIRM Forecast FAQ

Is Mirum Pharmaceuticals stock a buy?

Mirum Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mirum Pharmaceuticals is a favorable investment for most analysts.

What is Mirum Pharmaceuticals's price target?

Mirum Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $153.2 over the next 12 months. The price target range spans from $130 at the low end to $200 at the high end, suggesting a potential 84.36% change from the previous closing price of $83.1.

How does Mirum Pharmaceuticals stock forecast compare to its benchmarks?

Mirum Pharmaceuticals's stock forecast shows a 84.36% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Mirum Pharmaceuticals over the past three months?

  • October 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Mirum Pharmaceuticals’s EPS forecast?

Mirum Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0.62, marking a -231.91% decrease from the reported $-0.47 in 2025. Estimates for the following years are $2.92 in 2027, and $4.97 in 2028.

What is Mirum Pharmaceuticals’s revenue forecast?

Mirum Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $521.39M, reflecting a 0.01% increase from the reported $521.31M in 2025. The forecast for 2027 is $718.97M, and $919.96M for 2028.

What is Mirum Pharmaceuticals’s net income forecast?

Mirum Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $44.32M, representing a -289.68% decrease from the reported $-23.363M in 2025. Projections indicate $162.92M in 2027, and $203.34M in 2028.